Cyclacel Pharma (CYCC) Tops Q1 EPS by 13c

Cyclacel Pharma (NASDAQ: CYCC) reported Q1 EPS of ($2.77), $0.13 better than the analyst estimate of ($2.90).

“The global pandemic is creating uncertainty in every business sector and it is clear that we need novel, science-based solutions to emerge from the crisis,” said Spiro Rombotis, President and Chief Executive Officer. “While our priorities are ensuring patient safety and addressing our social responsibility, we remain committed to our business strategy of building an innovative pipeline addressing the rising problem of cancer resistance. Fadraciclib is establishing a leadership position among MCL1 suppressing compounds in clinical development. We are encouraged by observations of deep response and prolonged stable disease with tumor shrinkage in both intravenous schedules tested this far. Importantly, initial clinical data with oral fadraciclib show concordance with intravenous pharmacokinetics. After strengthening our balance sheet, we will now turn our attention to executing a precision medicine strategy to evaluate fadraciclib in patients with solid tumors and achieve our other clinical milestones through late 2022.”

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Stifel Starts Victrex Plc. (VCT:LN) (VTXPF) at Buy
• Ennis (EBF) Reports In-Line Q1 EPS